Gene clues could personalize myeloma treatment
NCT ID NCT07514052
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether certain gene activity patterns can predict how well the drug selinexor works in people with multiple myeloma that has come back or stopped responding to treatment. Researchers will give 127 participants a weekly selinexor combination and track their response using bone marrow tests and blood work. The goal is to move toward more personalized treatment for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Selinexor (a drug taken orally once a week, combined with other standard drugs)
- What this could lead to
- If successful, this could help doctors personalize treatment for multiple myeloma by using gene tests to predict who will benefit most from selinexor-based therapy.
- What could go wrong
- This is an early-stage study focused on finding predictive biomarkers, not proving a cure. The sample size is modest, and the results may not apply to all patients. Selinexor can cause side effects like nausea and fatigue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 127 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with multiple myeloma (MM) were enrolled if they had a confirmed diagnosis by bone marrow examination, relapsed/refractory disease after 2-4 prior lines of therapy, were aged ≥18 years, and provided written informed consent. Patients were excluded if they had unresolved toxicities from prior chemotherapy, severe comorbidities, or hypersensitivity to study drugs.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients with a confirmed diagnosis of multiple myeloma (MM) based on bone marrow aspiration or biopsy, in accordance with the International Myeloma Working Group (IMWG) criteria. 2. Patients with relapsed/refractory MM after 2-4 prior lines of therapy. 3. Age ≥18 years. 4. Provision of written informed consent, with willingness to participate in the study and to provide relevant clinical samples and follow-up information. Exclusion Criteria: 1. Patients with relapsed MM whose toxicities from prior chemotherapy have not recovered to baseline or ≤ Grade 1. 2. Presence of other active malignancies or severe systemic diseases (e.g., significant cardiovascular or cerebrovascular disease, hepatic or renal insufficiency) that may affect study outcomes or limit tolerance to treatment or follow-up. 3. Prior history of bone marrow transplantation or other treatments that may affect the bone marrow microenvironment or immune function within 6 months before study initiation. 4. Known hypersensitivity to selinexor, ixazomib, or any components of the study drugs, or a history of severe allergic reactions. 5. Known human immunodeficiency virus (HIV) infection (HIV antibody positive). 6. Participation in another clinical trial within 30 days prior to study initiation or during the study period. 7. Pregnant or breastfeeding women. 8. Patients with psychiatric disorders or those unable to comply with study procedures.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple myeloma of bone are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
ShanxiBethuneH
RECRUITINGTaiyuan, Shanxi, 030000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.